Bayer Schering granted approval to market oral contraceptive in Europe

Yaz will be launched in all major European markets in autumn 2008. Yaz is said to be the first oral contraceptive on the European market containing the unique progestin drospirenone combined with a low dose of ethinyl estradiol in a new dosing regimen of 24 days of active hormone tablets and four days of placebo.

Philip Smits, head of Bayer Schering Pharma’s business unit Women’s Healthcare, said: “Yaz offers women an innovative method of contraception with additional benefits, which other oral contraceptives do not have. Yaz, with its 24-day regimen and the mode of action of its progestin drospirenone, offers one-of-a-kind benefits to women.”